Rationale and early clinical data on IL-17 blockade in psoriasis

Expert Review of Clinical Immunology

Volumn 9, Issue 7, 2013, Pages 677-682

  Nwe, Steven M ^a   Champlain, Amanda H ^a   Gordon, Kenneth B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

brodalumab; IL 12 23; IL 17; ixekizumab; psoriasis vulgaris; secukinumab; Th17

Indexed keywords

BRODALUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; SECUKINUMAB;

ARTHRALGIA; BIOLOGICAL THERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHRODERMIC PSORIASIS; HEADACHE; HUMAN; IMMUNOPATHOGENESIS; INJECTION SITE REACTION; MOLECULAR RECOGNITION; NEUTROPENIA; PSORIASIS VULGARIS; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; TH17 CELLS;

EID: 84883233394     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.811034     Document Type: Review

References (64)

1. Hughes JE, Barraclough BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br. J. Psychiatry 143, 51-54 (1983).
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patientmembership survey. Arch. Dermatol. 137(3), 280-284 (2001).
3. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 14(4), 267-271 (2000).
4. Kimball AB, Gladman D, Gelfand JM et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 58(6), 1031-1042 (2008).
5. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int. J. Dermatol. 32(3), 188-190 (1993).
6. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J. Eur. Acad. Dermatol. Venereol. 15(1), 16-17 (2001).
7. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J. Am. Acad. Dermatol. 60(2), 218-224 (2009).
8. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann. Rheum. Dis. 70(Suppl. 1), i77-i84 (2011).
9. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 4(7), 441-447 (2003).
10. Prey S, Paul C, Bronsard V et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J. Eur. Acad. Dermatol. Venereol. 24(Suppl. 2), 31-35 (2010).
11. Shai A, Vardy D, Zvulunov A. Psoriasis, biblical afflictions and patients' dignity. Harefuah 141(5), 479-82, 496 (2002).
12. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263-271 (2007).
13. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N. Engl. J. Med. 301(10), 555 (1979).
14. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256(22), 3110-3116 (1986).
15. Gottlieb AB, Grossman RM, Khandke L et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98(3), 302-309 (1992).
16. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br. Med. J. (Clin. Res. Ed). 293(6549), 731-732 (1986).
17. Prens EP, van Joost T, Hegmans JP, Hooft-Benne K, Ysselmuiden OE, Benner R. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J. Am. Acad. Dermatol. 33(6), 947-953 (1995).
18. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11(1), 43-49 (2005).
19. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 109(9), 1139-1142 (2002).
20. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-And interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. 115(1), 81-87 (2000).
21. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104(1), 9-19 (2001).
22. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199(1), 125-130 (2004).
23. Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123(6), xiv-xxv (2004).
24. Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br. J. Dermatol. 153(5), 911-918 (2005).
25. Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin. Chim. Acta 394(1-2), 7-21 (2008).
26. Rømer J, Hasselager E, Nørby PL, Steiniche T, Thorn Clausen J, Kragballe K. Epidermal overexpression of interleukin-19 and-20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. 121(6), 1306-1311 (2003).
27. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111(4), 645-649 (1998).
28. Witowski J, Ksiazek K, Jörres A. Interleukin-17: a mediator of inflammatory responses. Cell. Mol. Life Sci. 61(5), 567-579 (2004).
29. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-And TNF-. J. Immunol. 162(1), 494-502 (1999).
30. Rich BE, Kupper TS. Cytokines: IL-20-A new effector in skin inflammation. Curr. Biol. 11(13), R531-R534 (2001).
31. Wolk K, Witte E, Warszawska K et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39(12), 3570-3581 (2009).
32. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80(2), 273-290 (2007).
33. Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122(2), 201-206 (2007).
34. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin. Immunol. 146(2), 131-139 (2013).
35. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 226, 57-79 (2008).
36. Hofstetter H, Gold R, Hartung HP. Th17 cells in MS and experimental autoimmune encephalomyelitis. Int. MS J. 16(1), 12-18 (2009).
37. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16(10), 1808-1813 (2010).
38. Crispín JC, Liossis SN, Kis-Toth K et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16(2), 47-57 (2010).
39. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 549-553 (2009).
40. Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med. 361(5), 496-509 (2009).
41. Conrad C, Boyman O, Tonel G et al. 11 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13(7), 836-842 (2007).
42. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 21(4), 467-476 (2004).
43. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71(1), 1-8 (2002).
44. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159(5), 1092-1102 (2008).
45. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Invest. Dermatol. 129(9), 2175-2183 (2009).
46. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al. Integrative responses to IL-17 and TNF-A in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131(3), 677-687 (2011).
47. Puzenat E, Bronsard V, Prey S et al. What are the best outcome measures for assessing plaque psoriasis severity A systematic review of the literature. J. Eur. Acad. Dermatol. Venereol. 24(Suppl. 2), 10-16 (2010).
48. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 58(5), 826-850 (2008).
49. Papp KA, Langley RG, Lebwohl M et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675-1684 (2008).
50. Griffiths CE, Strober BE, van de Kerkhof P et al.; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362(2), 118-128 (2010).
51. Gordon KB, Langley RG, Gottlieb AB et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 132(2), 304-314 (2012).
52. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165(3), 661-668 (2011).
53. Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165(3), 652-660 (2011).
54. Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365(17), 1586-1596 (2011).
55. Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-Analysis of randomized controlled trials. JAMA 306(8), 864-871 (2011).
56. Nakajima K, Kanda T, Takaishi M et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186(7), 4481-4489 (2011).
57. Hueber W, Patel DD, Dryja T et al.; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52-72 (2010).
58. Antoniu SA. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. Expert Opin. Investig. Drugs 21(11), 1607-1618 (2012).
59. Papp KA, Reid C, Foley P et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a Phase I, randomized, placebo-controlled trial. J. Invest. Dermatol. 132(10), 2466-2469 (2012).
60. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181-1189 (2012).
61. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190-1199 (2012).
62. Rich P, Sigurgeirsson B, Thaci DP et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, Phase II regimen-finding study. Br. J. Dermatol. doi:10.1111/bjd.12070 (2012) (Epub ahead of print).
63. Spuls PI, Hooft L. Brodalumab and ixekizumab, anti-interleukin-17- receptor antibodies for psoriasis: a critical appraisal. Br. J. Dermatol. 167(4), 710-713; discussion 714 (2012).
64. Hueber W, Sands BE, Lewitzky S et al.; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut 61(12), 1693-1700 (2012).